Whole-body MRI in patients with lymphoma: collateral findings

Galia, Massimo; Albano, Domenico; Narese, Donatella; Patti, Caterina; Chianca, Vito; Pietto, Francesco Di; Mulè, Antonino; Grassedonio, Emanuele; Grutta, Ludovico La; Lagalla, Roberto; Midiri, Massimo

doi:10.1007/s11547-016-0658-x

Cited by 21 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that MRI is a reliable tool for the detection of BMI by lymphoma . WB‐MRI provides images of the entire body, and overcomes the limits of local MRI, offering the possibility to study all potential sites of BMI, as well as to identify frequent complications such as osteonecrotic lesions …”

Section: Discussionmentioning

confidence: 99%

Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

Albano

Patti

Lagalla

et al. 2016

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

Albano

Patti

Lagalla

et al. 2016

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly to renal lesions, adrenal masses are often incidentally identified by abdominal imaging examinations, with non-hyperfunctioning adenomas representing the most common lesion [ 75 ]. Contrast-enhanced CT and chemical-shift MRI are generally used as helpful tools to characterize adrenal lesions [ 76 ].…”

Section: Urinary System and Adrenalmentioning

confidence: 99%

Diffusion-Weighted Imaging in Oncology: An Update

Messina

Bignone

Bruno

et al. 2020

Cancers

Self Cite

113

View full text Add to dashboard Cite

To date, diffusion weighted imaging (DWI) is included in routine magnetic resonance imaging (MRI) protocols for several cancers. The real additive role of DWI lies in the “functional” information obtained by probing the free diffusivity of water molecules into intra and inter-cellular spaces that in tumors mainly depend on cellularity. Although DWI has not gained much space in some oncologic scenarios, this non-invasive tool is routinely used in clinical practice and still remains a hot research topic: it has been tested in almost all cancers to differentiate malignant from benign lesions, to distinguish different malignant histotypes or tumor grades, to predict and/or assess treatment responses, and to identify residual or recurrent tumors in follow-up examinations. In this review, we provide an up-to-date overview on the application of DWI in oncology.

show abstract

“…There is no consensus on the best protocol for WB‐MRI in lymphoma. Different approaches have been proposed in previous studies including unenhanced T1‐ and T2‐weighted, short tau inversion recovery and diffusion‐weighted imaging (DWI) sequences . The “functional” evaluation is based on DWI through the visualization and quantification of the random Brownian motion of water molecules in the biologic tissues, assessed by apparent diffusion coefficient (ADC) .…”

Section: Wb‐mri: Main Aspects Of Its Use In Lymphomamentioning

confidence: 99%

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

Albano

Bruno

Patti

et al. 2019

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole‐body MRI (WB‐MRI) as a radiation‐free alternative to standard imaging procedures. WB‐MRI seems a less histology‐dependent functional imaging test than 18F‐fluorodeoxyglucose‐positron emission tomography/CT (18F‐FDG‐PET/CT). In patients with FDG‐avid lymphomas, such as diffuse large B‐cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18F‐FDG‐PET/CT remains the imaging reference standard for staging, with WB‐MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB‐MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB‐MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas.

show abstract

Whole-body MRI in patients with lymphoma: collateral findings

Abstract: WB-MRI is an attractive procedure that allows to detect incidental abnormalities of organs not involved by disease offering the opportunity to obtain an early diagnosis of asymptomatic life-threatening diseases.

Cited by 21 publications

References 31 publications

Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

Whole‐body MRI, FDG‐PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma

Diffusion-Weighted Imaging in Oncology: An Update

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

Contact Info

Product

Resources

About